Hexamethylene Amiloride: A Promising Agent Against Multiple Myeloma
Discover the groundbreaking research on Hexamethylene Amiloride, a novel compound showing significant efficacy in targeting multiple myeloma by inducing lysosome-mediated cell death and overcoming drug resistance. Learn about its molecular mechanisms and therapeutic potential.
Get a Quote & SampleProduct Core Value
5-(N,N-Hexamethylene)-Amiloride
As a leading supplier of high-quality pharmaceutical intermediates in China, we offer 5-(N,N-Hexamethylene)-Amiloride (CAS 1428-95-1), a potent inhibitor of the Na+/H+ exchanger 1 (NHE1). This compound has demonstrated significant anti-tumor effects, particularly in multiple myeloma (MM), by inducing apoptosis and lysosome-mediated cell death. Its unique mechanism of action and ability to overcome drug resistance make it a valuable agent in the development of novel cancer therapies.
- This compound is a key player in understanding cancer therapy resistance and developing new treatments for multiple myeloma.
- Its role as an NHE1 inhibitor highlights its potential in modulating intracellular pH, crucial for cancer cell survival.
- The research on Hexamethylene Amiloride provides valuable insights into lysosome-mediated cell death pathways, a critical area in oncology.
- As a pharmaceutical intermediate, it supports the advancement of targeted cancer therapies, offering hope for patients with difficult-to-treat conditions.
Advantages It Brings
Novel Therapeutic Mechanism
Leveraging its unique mechanism of lysosome-mediated cell death, this compound offers a new avenue for treating cancers resistant to conventional therapies, such as carfilzomib-resistant multiple myeloma.
Overcoming Drug Resistance
Our research indicates that Hexamethylene Amiloride can effectively overcome carfilzomib resistance in multiple myeloma cells, potentially enhancing the efficacy of existing treatments and offering solutions for relapsed or refractory cases.
In Vivo Efficacy Demonstrated
Studies have confirmed the anti-myeloma efficacy of Hexamethylene Amiloride in vivo, showing significant inhibition of tumor growth in preclinical models, underscoring its therapeutic promise.
Key Applications
Multiple Myeloma Treatment
Investigating the potential of Hexamethylene Amiloride as a targeted therapy for multiple myeloma, focusing on its role in inducing apoptosis and overcoming drug resistance.
Cancer Drug Development
Utilizing Hexamethylene Amiloride as a pharmaceutical intermediate to develop novel anti-cancer agents, particularly those targeting cell signaling pathways like NHE1.
Cell Death Pathway Research
Studying the molecular mechanisms of lysosome-mediated cell death, with Hexamethylene Amiloride serving as a key compound to elucidate the role of TFE3 and lysosomal integrity in cancer.
Drug Resistance Studies
Exploring how Hexamethylene Amiloride can reverse resistance to established chemotherapies, offering new combinatorial strategies for improved patient outcomes.